Exagen Inc. (XGN) Institutional Ownership

Ownership Summary

Exagen Inc. (NASDAQ:XGN) currently has 10 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• Institutional ownership in Exagen edged down to 5.6% in December 2025, compared to 43.7% in September 2025.
• Institutional share ownership changed by 3.03% QoQ, while the number of institutional owners saw a decrease of 76.19% YoY.
• Of these 10 institutional investors, 4 increased their holdings in Exagen, while 5 of them reduced positions, and 1 investors maintained their exposure.
• The aggregate institutional position in Exagen now stands at 1.17Mn shares as of December 2025, after investors increased their holdings (up by 34.25K shares quarter on quarter which is down 4.95Mn shares year over year).
• As of December 31, 2025, VANGUARD GROUP INC held Exagen's largest shareholding position with over 790.01K shares, representing 3.82% of total outstanding shares.
• Among the most significant buyers of Exagen during December 2025 were VANGUARD GROUP INC (56.19K), UBS Group AG (22.98K), R Squared Ltd (18.19K), Palumbo Wealth Management LLC (5.72K).
• Leading sellers of Exagen stock in December 2025 included Huntleigh Advisors, Inc. (36.16K), Calamos Advisors LLC (21.78K), Penbrook Management LLC (6.48K), CITIZENS FINANCIAL GROUP INC/RI (2.90K), PERKINS CAPITAL MANAGEMENT INC (1.50K).
• The top 10 institutional holders of Exagen for the quarter ending December 2025 included VANGUARD GROUP INC (790.01K), UBS Group AG (112.99K), Huntleigh Advisors, Inc. (57.19K), Calamos Advisors LLC (56.31K), CITIZENS FINANCIAL GROUP INC/RI (54.62K), Palumbo Wealth Management LLC (43.34K), PERKINS CAPITAL MANAGEMENT INC (18.57K), R Squared Ltd (18.19K), Penbrook Management LLC (13.43K), CWM, LLC (1.40K).